ATARAX (hydroxyzine) - Risk of QT Prolongation and Torsade de Pointes

A Health Canada safety review has demonstrated that ATARAX (hydroxyzine) has the potential to block hERG channels and other types of cardiac channels, resulting in a potential risk of QT prolongation (QTP) and cardiac arrhythmia events including torsade de pointes (TdP).